The Boston Globe
By Deborah Kotz | GLOBE STAFF JULY 09, 2014
ADHD drugs require greater safety studies
A study just published in the journal PLOS One by Boston Children’s Hospital researchers revealed that most stimulant drugs for ADHD obtaining FDA approval were tested on too few patients for only weeks rather than months and were based on efficacy rather than long term safety.
Co-author Mandl and his colleagues also found that the FDA requested six follow-up safety studies from drug manufacturers to assess long-term safety risks but that only two of these studies were ever conducted.
According to Dr. Harold Levinson and many others, it is very important to implement more stringent approval procedures for drugs that are taken long term by a huge population of both children and adults. However, most of these stimulants have been used for half a century. And much is known about them compared to newly created drugs without a background history.
Having followed thousands of children properly treated and monitored for decades, their long term effects seem mostly positive. Recent studies have demonstrated that early treatment of young children may even help minimize the risks of addiction and child abuse reported in untreated adults.
About Harold Levinson, M.D.:
Formerly Clinical Associate Professor of Psychiatry at New York University Medical Center, Dr. Harold Levinson is currently Director of the Levinson Medical Center for Learning Disabilities in Long Island, New York. He is a well-known neuropsychiatrist, clinical researcher and author. For more information, call 1(800)334-7323 or visit: http://www.dyslexiaonline.com.
Image courtesy of Scott Chan FreeDigital Photos.net